OBJECTIVE: Evaluate the effect of sex and butyrylcholinesterase (BuChE) genotype on the incidence of Alzheimer's disease (AD), cognitive and functional decline, brain volume changes, and response to rivastigmine treatment in individuals with mild cognitive impairment (MCI). METHODS: This retrospective exploratory analysis from a 3-4 year, randomized, placebo-controlled study of rivastigmine in MCI patients included participants who consented to pharmacogenetic testing. RESULTS:Of a total of 1018 patients, 490 [253 (52%) female] were successfully genotyped for BuChE. In patients receiving placebo, the BuChE wt/wt genotype was associated with a statistically significant higher incidence of progression to AD and functional decline in women, compared with men with the BuChE wt/wt genotype. In patients with a BuChE-K allele receiving placebo, incidence of progression to AD and rate of functional decline were not significantly different by sex; however, cognitive decline was significantly faster in men. Statistically significant benefits of rivastigmine treatment on incident AD, functional decline, ventricular volume expansion, whole-brain atrophy, and white matter loss were evident in female BuChE wt/wt. CONCLUSION: Sex and BuChE genotype seem to differentially influence the type of decline in MCI patients, with more rapid progression of cognitive decline in male BuChE-K, and more incident AD and functional decline in female BuChE wt/wt. Cognitive decline in male BuChE-K and functional decline and incident AD in female BuChE wt/wt were significantly attenuated by rivastigmine. Rivastigmine treatment also significantly reduced ventricular expansion, whole-brain atrophy rate, and white matter loss in female BuChE wt/wt, suggesting a possible disease-modifying effect.
RCT Entities:
OBJECTIVE: Evaluate the effect of sex and butyrylcholinesterase (BuChE) genotype on the incidence of Alzheimer's disease (AD), cognitive and functional decline, brain volume changes, and response to rivastigmine treatment in individuals with mild cognitive impairment (MCI). METHODS: This retrospective exploratory analysis from a 3-4 year, randomized, placebo-controlled study of rivastigmine in MCI patients included participants who consented to pharmacogenetic testing. RESULTS: Of a total of 1018 patients, 490 [253 (52%) female] were successfully genotyped for BuChE. In patients receiving placebo, the BuChE wt/wt genotype was associated with a statistically significant higher incidence of progression to AD and functional decline in women, compared with men with the BuChE wt/wt genotype. In patients with a BuChE-K allele receiving placebo, incidence of progression to AD and rate of functional decline were not significantly different by sex; however, cognitive decline was significantly faster in men. Statistically significant benefits of rivastigmine treatment on incident AD, functional decline, ventricular volume expansion, whole-brain atrophy, and white matter loss were evident in female BuChE wt/wt. CONCLUSION: Sex and BuChE genotype seem to differentially influence the type of decline in MCI patients, with more rapid progression of cognitive decline in male BuChE-K, and more incident AD and functional decline in female BuChE wt/wt. Cognitive decline in male BuChE-K and functional decline and incident AD in female BuChE wt/wt were significantly attenuated by rivastigmine. Rivastigmine treatment also significantly reduced ventricular expansion, whole-brain atrophy rate, and white matter loss in female BuChE wt/wt, suggesting a possible disease-modifying effect.
Authors: Jacques Touchon; Howard Bergman; Roger Bullock; Günter Rapatz; Jennifer Nagel; Roger Lane Journal: Curr Med Res Opin Date: 2006-01 Impact factor: 2.580
Authors: Nigel H Greig; Tadanobu Utsuki; Donald K Ingram; Yue Wang; Giancarlo Pepeu; Carla Scali; Qian-Sheng Yu; Jacek Mamczarz; Harold W Holloway; Tony Giordano; DeMao Chen; Katsutoshi Furukawa; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri Journal: Proc Natl Acad Sci U S A Date: 2005-11-07 Impact factor: 11.205
Authors: Andrea C Tricco; Charlene Soobiah; Shirra Berliner; Joanne M Ho; Carmen H Ng; Huda M Ashoor; Maggie H Chen; Brenda Hemmelgarn; Sharon E Straus Journal: CMAJ Date: 2013-09-16 Impact factor: 8.262
Authors: E Rodríguez-Rodríguez; P Sánchez-Juan; J L Vázquez-Higuera; I Mateo; A Pozueta; J Berciano; S Cervantes; D Alcolea; P Martínez-Lage; J Clarimón; A Lleó; P Pastor; O Combarros Journal: J Neural Transm (Vienna) Date: 2012-11-20 Impact factor: 3.575
Authors: Elijah Mak; Li Su; Guy B Williams; Michael J Firbank; Rachael A Lawson; Alison J Yarnall; Gordon W Duncan; Brit Mollenhauer; Adrian M Owen; Tien K Khoo; David J Brooks; James B Rowe; Roger A Barker; David J Burn; John T O'Brien Journal: Neurobiol Aging Date: 2017-03-16 Impact factor: 4.673